Revised SPC: Kisqali (ribociclib) tablets

SPC now states that toxic epidermal necrolysis has been reported with use. If signs and symptoms suggestive of severe cutaneous reactions (e.g. progressive widespread skin rash often with blisters or mucosal lesions) appear, it should be discontinued immediately.

Source:

electronic Medicines compendium